Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Synthetic lethality describes a situation in which defects in either one of two genes are not detrimental, but combining defects in the two genes is lethal. The targeting of BRCA-deficient tumors by PARP inhibitors is the first clinical example utilizing the principle of synthetic lethality to treat cancer. Despite the promise of this approach, a n...
Alternative Titles
Full title
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1449769369
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1449769369
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/nm.3369
